Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Míreanna Comhchosúla

• Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration
  le: Rosengren, Sanna, et al.
  Foilsithe: (2015)
• In-Vivo Efficacy of Recombinant Human Hyaluronidase (rHuPH20) Injection for Accelerated Healing of Murine Retrocalcaneal Bursitis and Tendinopathy
  le: Rezvani, Sabah N., et al.
  Foilsithe: (2019)
• A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
  le: Printz, Marie A., et al.
  Foilsithe: (2020)
• Subcutaneous Heparin With and Without Hyaluronidase
  le: Hollman, Arthur, et al.
  Foilsithe: (1957)
• Accelerating and Improving the Consistency of Rapid-Acting Analog Insulin Absorption and Action for Both Subcutaneous Injection and Continuous Subcutaneous Infusion Using Recombinant Human Hyaluronidase
  le: Muchmore, Douglas B., et al.
  Foilsithe: (2012)